
A review of overall survival extrapolations of immune-checkpoint inhibitors used in health technology assessments by the French Health Authorities

**Supplementary files**


Supplementary Materials 1

Study 2: CheckMate 017




**Figure S 1.** Overall survival (left) and hazard rate (right) of nivolumab in CheckMate 017

Study 3: CheckMate 057




**Figure S 2.** Overall survival (left) and hazard rate (right) of nivolumab in CheckMate 057

Study 4: CheckMate 066




**Figure S 3**. Overall survival (left) and hazard rate (right) of nivolumab in CheckMate 066

Study 5: CheckMate 025




**Figure S 4.** Overall survival (left) and hazard rate (right) of nivolumab in CheckMate 025

Study 7: KeyNote 010




**Figure S 5.** Overall survival (left) and hazard rate (right) of pembrolizumab in KeyNote 010

Study 7: KeyNote 006



**Figure S 6.** Overall survival (left) and hazard rate (right) of pembrolizumab in KeyNote 006

Study 11 : KeyNote 045



**Figure S 7.** Overall survival (left) and hazard rate (right) of pembrolizumab in KeyNote 045

# Supplementary Materials 2

Computerized algorithm designed for extracting all the references analysed in the literature review

(atezolizumab [Title/Abstract] OR durvalumab [Title/Abstract] OR ipilimumab [Title/Abstract] OR nivolumab [Title/Abstract] OR nivolumab AND ipilimumab [Title/Abstract] OR pembrolizumab [Title/Abstract] AND aok [Title/Abstract] OR impower 150 [Title/Abstract] OR pacific [Title/Abstract] OR melbase [Title/Abstract] OR checkmate 017 [Title/Abstract] OR checkmate 025 [Title/Abstract] OR checkmate 057 [Title/Abstract] OR checkmate 066 [Title/Abstract] OR checkmate 141 [Title/Abstract] OR checkmate 214 [Title/Abstract] OR checkmate 238 [Title/Abstract] OR keynote 006 [Title/Abstract] OR keynote 010 [Title/Abstract] OR keynote 024 [Title/Abstract] OR keynote 045 [Title/Abstract] OR keynote 054 [Title/Abstract] OR keynote 189 [Title/Abstract] OR keynote 407 [Title/Abstract])

# Supplementary Materials 3



**Figure S 8**. Absolute percentage point difference between extrapolated and observed OS in extended follow-up of RCT

# Supplementary Materials 4

**Figure S 9**. Relationship between relative differences and maturity of data at the time of the submission

Maturity of data corresponds to the number of events at the time of the submission

N.B: Maturity of data was not available for KeyNote 045

**Cancer type**: M: melanoma; NSCLC: non-small-cell lung cancer; RCC: renal cell carcinoma; UC: urothelial carcinoma

**Therapy**: ICI: Immune checkpoint inhibitor; CT: chemotherapy; D: durvalumab; I: ipilimumab; N: nivolumab; P: pembrolizumab.

**Extrapolation function**: exp: exponential; GG: generalized gamma; HR: hazard ratio; KM: Kaplan-Meier; LL: log logistic; LN: log normal; nov: novel approach; Spline-2k-N: Spline 2-knot – normal.